GlassScriptPhysician profile
Edward Horvath
NPI 1124131164
$18,071.67
in general payments reported to CMS, 2019-2025
41 companies · $2,910 in 2025
The $2,910 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,324 · 2020: $1,967 · 2021: $2,687 · 2022: $2,489 · 2023: $3,214 · 2024: $2,481 · 2025: $2,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,659 · Travel and Lodging: $885 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,658.61 |
| Travel and Lodging | $884.74 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,624.30 | 2019-2025 | |
| Janssen Biotech, INC. | $1,506.09 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,285.61 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,194.86 | 2019-2025 | Xifaxan, Trulance |
| Medtronic, INC. | $1,165.06 | 2022-2024 | Interstim |
| Pfizer INC. | $982.96 | 2019-2025 | |
| Qol Medical, LLC | $866.69 | 2019-2024 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $814.22 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $793.55 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $618.14 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $541.52 | 2019-2024 | Ocaliva |
| Madrigal Pharmaceuticals | $433.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $334.54 | 2019-2024 | Suflave, Sutab |
| Ardelyx, INC. | $331.95 | 2024-2025 | Ibsrela |
| Redhill Biopharma INC. | $303.70 | 2020-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $268.40 | 2024-2025 | Voquezna |
| Celgene Corporation | $268.18 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $243.19 | 2019-2025 | Therasphere Y90 Glass Microspheres 10 Gbq, General - Polypectomy |
| Ferring Pharmaceuticals INC. | $232.15 | 2019-2025 | Rebyota |
| Lilly USA, LLC | $222.22 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $219.76 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $204.54 | 2023 | Dupixent |
| Ucb, INC. | $201.91 | 2019-2021 | |
| Galvanize Therapeutics, INC | $186.24 | 2025 | Aliya System |
| Allergan, INC. | $181.41 | 2019-2020 | |
| Vivus LLC | $154.73 | 2019-2025 | Qsymia, Pancreaze |
| Ironwood Pharmaceuticals, INC | $151.52 | 2020-2024 | |
| Genzyme Corporation | $136.33 | 2022-2025 | |
| Genentech, INC. | $125.93 | 2025 | |
| Aimmune Therapeutics, INC. | $97.42 | 2024-2025 | Vowst |
| Micro-Tech Endoscopy USA, INC. | $80.31 | 2022-2025 | Dat Device, Lesionhunter, Snare |
| Erbe USA INC | $65.00 | 2024 | |
| Olympus America INC. | $53.25 | 2019 | |
| Romark Laboratories, Lc | $41.60 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.87 | 2025 | Givlaari |
| Biocon Biologics INC | $24.75 | 2025 | Yesintek |
| Concordia Pharmaceuticals INC. | $23.50 | 2019 | |
| Amgen INC. | $20.33 | 2023 | Avsola |
| Ethicon US, LLC | $17.36 | 2022 | |
| Alfasigma USA, INC. | $15.16 | 2020 | |
| Organon LLC | $14.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Horvath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.